




Contact:
Amos Adler M.Sc., CEO
amos@a4i.me
<https://www.a4i.me>



A4i (App4Independence) is a digital therapeutic (DTx) and digital biomarker platform for severe mental illnesses (SMIs).

The platform features a mobile application used by patients and a clinical web portal to support care coordination by providers. A4i is a trans-diagnostic platform which has cross-cutting applications across many SMIs. The platform has active deployments to manage schizophrenia. **A4i addresses critical gaps during pivotal points in the recovery process by providing (patent pending) tools that address auditory hallucinations, data collection for clinical decision support and data-driven readmission/relapse risk-detection.** Additional solutions are being developed to address indications for addictions (e.g. opioid use disorder), severe mood (e.g., bipolar disorder), and developmental disability populations.

A4i is a Joint Venture between Canada's largest mental health teaching hospital, The Centre for Addiction & Mental Health (CAMH) and MEMOTEXT, a leading provider for digital patient engagement and DTx solutions.

Severe Mental Illness

Complex patient journeys, very limited in-person outpatient care resources, challenged provider and treatment plan engagement with high non-adherence rates, high rates of risk and distress alongside extensive and costly crisis service utilization.

- **23%** are readmitted within 30 days of discharge.
- **\$470 Billion** in direct costs to healthcare
- **\$500+ Billion** Total Addressable Market.

Traction

- Expanding clinical pilots doubling ARR for 3 years
- Early contracts from multiple (US + CDN) providers
- Early validation peer-reviewed with multiple publications: [PLOS One](#) and [Frontiers in Psychiatry](#).
- Nationally funded (CIHR) Randomized Control Trial underway
- J&J JLABs Quickfire challenge winner
- OBIO Early Adopter Health Network Company

About Us

- Deep clinical and commercialization team Dr. Sean Kidd PhD, Chief Science Officer (Division Chief Psychology CAMH)
- Amos Adler M.Sc. 11 years digital health commercialization
- Creative Destruction Labs (CDL) Accelerator Health Diagnostics Graduate
- Scientific American's 1 of 10 startups changing healthcare

Value of A4i

A4i is co-designed with patients and clinicians using a transdiagnostic approach to multi-symptom remediation

- Enhanced clinical decision support through highly adaptive patient-provider engagement and communications
- **Readmission-risk prediction through proactive analytics and predictive machine learning**
- Significant early improvements in several symptom domains
- Early digital biomarkers (feature predictors) identified related to risk of relapse/readmission.
- **Patent(s) Pending: Audio hallucination detection feature**
- Regulatory (FDA) pathway towards Software as a Medical Device (SaMD)
- Multiple use-cases for SMIs: Opioid Use Disorder, Major Depressive Disorder, Bipolar Disorder



Dr. Sean Kidd PhD, CSO & Division Chief Psychology Centre for Addictions & Mental Health

